广州智瓴生物医药

Zhiling Biomedical is a clinical-stage biotechnology company headquartered in Guangzhou, China, dedicated to developing innovative cell therapies for solid tumors. Founded by industry veterans with expertise in T-cell and NK-cell engineering, the company leverages its proprietary "eNK" platform to create off-the-shelf, highly potent engineered Natural Killer cell products. Their primary focus is addressing the challenges of the immunosuppressive tumor microenvironment that often hinder the efficacy of traditional cell therapies. The company's lead candidate, ZL-N101, is a CAR-NK therapy targeting Mesothelin-expressing solid tumors, currently undergoing clinical evaluation in investigator-initiated trials. Zhiling's pipeline also includes programs targeting Glypican-3 and other validated tumor antigens. By utilizing an allogeneic approach, the company aims to provide more accessible and cost-effective treatment options for cancer patients. The firm has secured significant backing from prominent venture capital firms to accelerate its research and manufacturing capabilities.